Skip to content

Ponoi Management, LLC

Follow

13F filer, CIK 1720702, San Francisco, CA

Ponoi Management, LLC reported $73,242,000 across 4 holdings for the quarter ended 2022-09-30, in a 13F-HR filed 2022-11-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-22-012318

Period
2022-09-30
Reported value
$73.2M
Holdings
4
Top 10 weight
100%
New
0
Sold out
0

Holdings, Q3 2022

Share positions as resolved from 13F-HR 0000950123-22-012318, largest first. % of portfolio is the value over $73,242,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q4: 1,599,417 shares; 2021Q1: 1,599,417 shares; 2021Q2: 1,599,417 shares; 2021Q3: 1,599,417 shares; 2021Q4: 1,599,417 shares; 2022Q1: 1,599,417 shares; 2022Q2: 1,599,417 shares; 2022Q3: 1,599,417 shares 1,599,417$38.5M52.54%0
NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q4: 1,298,908 shares; 2021Q1: 1,298,908 shares; 2021Q2: 1,298,908 shares; 2021Q3: 1,298,908 shares; 2021Q4: 1,298,908 shares; 2022Q1: 1,298,908 shares; 2022Q2: 1,298,908 shares; 2022Q3: 1,298,908 shares 1,298,908$17M23.2%0
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q4: 685,011 shares; 2021Q1: 685,011 shares; 2021Q2: 685,011 shares; 2021Q3: 685,011 shares; 2021Q4: 685,011 shares; 2022Q1: 685,011 shares; 2022Q2: 685,011 shares; 2022Q3: 685,011 shares 685,011$13.5M18.44%0Timeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q4: 686,274 shares; 2021Q1: 686,274 shares; 2021Q2: 686,274 shares; 2021Q3: 561,573 shares; 2021Q4: 327,122 shares; 2022Q1: 327,122 shares; 2022Q2: 327,123 shares; 2022Q3: 327,123 shares 327,123$4.26M5.82%0Timeline

How Q3 2022 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-22-012318 base2022-11-14acceptance time not in the bulk data set